Coapt said it licensed implantable technology from the Purdue Research Foundation for implantable electrodes used to amplify the signal between muscles and prosthetic limbs.
Chicago-based Coapt said it plans to use the subcutaneous electrodes in conjunction with its Complete Control system, which is designed to decode the signals for more intuitive feeling and control for the amputee.
“Our revolutionary control technologies allow amputees to regain their independence with a system that controls their prostheses better than ever before,” co-founder & CEO Blair Lock said in prepared remarks. “Our exclusive licensing of Purdue’s implantable technology is a game-changer in prosthetics and orthotics. With this next generation tool in our portfolio, Coapt expands its position as the industry leader in the field of intuitive control.”
“The group at Coapt has developed significant talent and resources, so they are the ideal partner to make this implantable technology available to those who need it,” added Chad Pittman, vice president of the Purdue Research Foundation’s technology commercialization office. “With this license and their innovative expertise, they truly can change the lives of amputees.”